TAK 214

Drug Profile

TAK 214

Alternative Names: Norovirus bivalent vaccine - Takeda; Norovirus bivalent VLP vaccine; Norovirus GI.1/GII.4 bivalent VLP vaccine; Norovirus IM vaccine - Takeda; Norovirus intramuscular vaccine - Takeda; TAK-214

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Takeda
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Norovirus infections

Most Recent Events

  • 04 Oct 2017 Immunogenicity and adverse events data from a phase II trial in Norovirus infections presented at the IDWeek 2017 (IDW-2017)
  • 29 Sep 2017 Takeda completes a phase II trial in Norovirus infections (In volunteers, In the elderly, In adults) in USA (IM) (NCT02661490)
  • 21 Feb 2017 Takeda initiates enrolment in a phase II trial for Norovirus infections (Prevention) in USA (IM) (NCT03039790)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top